Business Context and Reporting Period
Company: Matinas BioPharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: July 10, 2026
Reporting Period: Events occurring on July 10, 2026, with transactions expected to close in Q4 2026.
Matinas BioPharma Holdings, Inc. announced a Business Combination with GH Power Inc. (via Pubco), the sale of its subsidiary Matinas BioPharma Nanotechnologies, Inc. (Matinas Nano) to Azurity Pharmaceuticals, Inc., and concurrent financing activities including a Series D PIPE and a Warrant Inducement.
Key Financial Metrics and Transaction Values
Business Combination Valuation (Pro Forma):
- Matinas BioPharma Valuation: $24,725,274.73
- GH Power Valuation: $250,000,000.00
- Expected Ownership Post-Closing: Matinas shareholders ~9%; GH Power shareholders ~91%.
Stock Sale (Matinas Nano to Azurity):
- Total Consideration: Up to $21,500,000.
- Upfront Cash: $4,000,000 (subject to debt adjustment).
- Milestone Payments: Up to $17,500,000.
- Royalties: Mid-single-digit royalty on Net Sales and Licensing Proceeds for MAT2203.
- Preferred Stockholder Participation: Series A holders entitled to 7.5% of proceeds.
Financing Activities (Matinas PIPE & Warrant Inducement):
- Series D PIPE: Issuance of 575 shares of Series D Preferred Stock ($1,000 stated value) and warrants for gross proceeds of $575,000.
- Warrant Inducement: Gross proceeds of approximately $2.6 million from the exercise of existing warrants.
- Combined Net Proceeds: Intended for working capital and general corporate purposes.
Debt and Liquidity: The filing does not provide specific current cash balances or total debt figures. The Stock Sale consideration is subject to downward adjustment by the amount of Indebtedness.
Material Changes and Transaction Terms
Business Combination Structure:
- Matinas will become a wholly-owned subsidiary of Pubco.
- Exchange Ratio: Each Matinas Common Share converts to 0.1 Pubco Common Share.
- Options and Warrants: Converted to Pubco equivalents with adjusted exercise prices (divided by 0.1).
- Advisor Fee: A former financial advisor to receive $2.0 million cash and $2.0 million in Pubco Common Shares upon closing.
Stock Sale Terms:
- Matinas Nano (f/k/a Aquarius Biotechnologies) will be sold to Azurity.
- Transaction is conditioned on the closing of the Business Combination.
- Termination Fee: Matinas may owe Azurity $400,000 under specified termination scenarios.
Securities Issuance:
- Series D Preferred Stock: Convertible at $0.35 per share (post-approval).
- Warrant Inducement: New warrants issued at $0.35 exercise price for 100% of shares underlying exercised existing warrants.
- Anti-Dilution Adjustments: Existing warrant exercise price adjusted from $0.6446 to $0.35; Series C Preferred conversion price adjusted from $0.586 to $0.35.
Guidance, Outlook, Risks, and Contingencies
Outlook and Timeline:
- Business Combination expected to close in Q4 2026.
- Outside Date for closing: December 31, 2026 (extendable by 60 days under specific conditions).
- Pubco expected to list on NYSE.
Key Conditions to Closing:
- Completion of GH Power PIPE Financing (minimum $15.0 million gross proceeds).
- Stockholder approval from both Matinas and GH Power.
- Effectiveness of Form F-4 Registration Statement.
- Pubco qualification as a foreign private issuer.
Risks and Contingencies:
- Termination Fees: Up to $1.0 million payable by either party plus expense reimbursements ($250k for GH Power, $500k for Matinas) upon termination under specific circumstances.
- Regulatory Risk: Failure to obtain required stockholder approvals or regulatory orders.
- Financing Risk: Failure to raise the required $15.0 million PIPE financing for GH Power.
- Forward-Looking Statements: Actual results may differ due to market conditions, regulatory changes, and failure to realize anticipated benefits.
Investor Verification Checklist
- Stockholder Approval: Verify the outcome of the Special Stockholder Meeting required for the Business Combination, Stock Sale, PIPE, and Warrant Inducement.
- GH Power PIPE Financing: Confirm that GH Power has secured the minimum $15.0 million in gross proceeds required to close the Business Combination.
- Form F-4 Filing: Monitor the filing and effectiveness of the proxy statement/prospectus (Form F-4) for detailed terms and risk factors.
- Matinas Nano Sale: Confirm the closing of the Stock Sale with Azurity and the receipt of the $4.0 million upfront payment.
- CEO Compensation: Note the $199,333.33 retention bonus payable to CEO Jerome D. Jabbour upon execution of the BCA, with the remainder due at closing.
- Board Composition: Verify the final composition of the Post-Closing Pubco Board (1 Matinas designee, 4 GH Power designees).